Biotech Begins Gene Therapy Trial for Vision Loss
Life Biosciences has started dosing patients in a Phase 1 trial of ER-100, an experimental gene therapy aimed at age-related vision loss.
Updated on Nov. 22, 2026 in Biotech

Live Poll
Do you trust experimental gene therapies to be worth their risks?
The FDA cleared the first-in-human Phase 1 trial of ER-100 in January 2026, and patient dosing began in June 2026. The therapy targets patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, conditions for which no approved treatments currently exist.
Why it matters
The trial tests whether a one-time gene therapy can address vision loss that current options do not treat. ER-100 has shown vision-restoration potential in primate studies, but it has not been approved as a commercial treatment or established as a cure.
The Phase 1 trial uses a modified virus delivered by a single eye injection to introduce three reprogramming factors into retinal ganglion cells, with patients taking oral doxycycline for eight weeks to control gene activation. Human efficacy and safety data remain unavailable until early readouts expected in late 2026.
The players
Life Biosciences
A Boston-based biotechnology company developing ER-100 and other gene-based approaches to age-related disease.
David Sinclair
A Harvard Medical School geneticist and co-founder of Life Biosciences, known for research on aging and cellular reprogramming.
The details
Life Biosciences, a Boston-based biotech company co-founded by Harvard Medical School geneticist David Sinclair, is developing ER-100. Patients receive a single eye injection of a modified virus, then take oral doxycycline for eight weeks to regulate the therapeutic genes.
Timeline
January 2026: FDA granted Investigational New Drug clearance for ER-100.
June 2026: Patient dosing started in the Phase 1 trial.
Late 2026: Early clinical readouts are expected.
May 2027: Primary completion of the clinical trial is expected.
Roadmap
ER-100 applies the Yamanaka reprogramming factors, first identified as a route to induced pluripotent stem cells, in a human eye-treatment trial. The approach moves partial cellular reprogramming from laboratory and animal work toward clinical testing in patients with conditions lacking approved therapies.
If the trial succeeds, patients with glaucoma or optic neuropathy could gain a treatment option where none exists today. For now, the therapy remains investigational and is not available outside the clinical trial.
The takeaway
Gene therapies aimed at restoring vision are moving from animal studies into human testing, but early-stage trials cannot yet show whether they will work. Readers should watch for the late-2026 readouts before drawing conclusions about ER-100's potential.
What happens next
Early clinical readouts from the ER-100 trial are expected in late 2026, with primary completion of the study expected in May 2027.
Further reading
Explore more biotech coverage from the Boston region.
Source note: This article includes information reported by The News International.
Live Poll
Do you trust experimental gene therapies to be worth their risks?






